Titre:
  • Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Auteur:André, Thierry; Lonardi, Sara; Wong, Ka Yeung Mark; Lenz, Heinz-Josef; Gelsomino, Fabio; Aglietta, M.; Morse, Michael Andew; Van Cutsem, Eric; McDermott, Ray; Hill, Andrew; Sawyer, Michael M.B.; Hendlisz, Alain; Neyns, Bart; Abdullaev, Sandzhar; Memaj, Arteid; Lei, Ming; Dixon, Matthew; Kopetz, Scott; Overman, Michael James
Informations sur la publication:Annals of oncology
Statut de publication:Publié, 2022
Sujet CREF:Cancérologie
Hématologie
Mots-clés:colorectal cancer
immune checkpoint inhibitor
ipilimumab
metastatic
MSI-H/dMMR
nivolumab
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1016/j.annonc.2022.06.008
info:pii/S0923753422017379
info:scp/85135508049
info:pmid/35764271